Cancers of the brain and nervous system affect both adults and children and come in several different forms. However, the cause and treatment of neurological cancers are still not well understood. Although significant advances have been made in understanding the biology of these cancers—as well as in tumor diagnosis, treatments, and quality of life of patients with the disease—the mortality rate has remained steady for more than 30 years.
Worldwide, an estimated 308,000 people were diagnosed with a primary brain or spinal cord tumor in 2020. Brain and nervous system cancers account for 1 in every 100 cancer diagnoses and are two of the primary cancers that affect children and young adults. There has been little progress in the field of treatment in many forms of brain cancer for several years. In 2005, a chemotherapy agent temozolomide was approved for the treatment of certain gliomas, but over 50% of patients developed resistance to this form of therapy. Alternative therapies are sorely needed to offer different approaches to target neurological cancers.
This Research Topic will focus on the current research on immunotherapy in brain cancers. Original research should present new data from clinical or basic research. Review articles should analyze and discuss previous research, with innovative and critical observations. Important topics to discuss include but are not limited to:
1) Manuscripts surrounding therapies such as Conjugated, Naked and Bispecific Monoclonal Antibodies in adult neurological cancers.
2) Adoptive Cell Therapies from Tumor-infiltrating lymphocyte (TIL) therapy, CAR T-cell therapy, and Natural killer (NK) cell therapy and the roles these can play in adult neurological cancers.
3) Immune Checkpoint Inhibitors from PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors and the targeting of adult neurological cancers.
4) Clinical management of patients with neurological cancers who undergo immunotherapy treatments.
5) The relationship between immunotherapy and CNS complications.
Please note: This Research Topic will not accept manuscripts that consist solely of bioinformatics analysis of public databases and are not accompanied by clinical or biological validation.
Cancers of the brain and nervous system affect both adults and children and come in several different forms. However, the cause and treatment of neurological cancers are still not well understood. Although significant advances have been made in understanding the biology of these cancers—as well as in tumor diagnosis, treatments, and quality of life of patients with the disease—the mortality rate has remained steady for more than 30 years.
Worldwide, an estimated 308,000 people were diagnosed with a primary brain or spinal cord tumor in 2020. Brain and nervous system cancers account for 1 in every 100 cancer diagnoses and are two of the primary cancers that affect children and young adults. There has been little progress in the field of treatment in many forms of brain cancer for several years. In 2005, a chemotherapy agent temozolomide was approved for the treatment of certain gliomas, but over 50% of patients developed resistance to this form of therapy. Alternative therapies are sorely needed to offer different approaches to target neurological cancers.
This Research Topic will focus on the current research on immunotherapy in brain cancers. Original research should present new data from clinical or basic research. Review articles should analyze and discuss previous research, with innovative and critical observations. Important topics to discuss include but are not limited to:
1) Manuscripts surrounding therapies such as Conjugated, Naked and Bispecific Monoclonal Antibodies in adult neurological cancers.
2) Adoptive Cell Therapies from Tumor-infiltrating lymphocyte (TIL) therapy, CAR T-cell therapy, and Natural killer (NK) cell therapy and the roles these can play in adult neurological cancers.
3) Immune Checkpoint Inhibitors from PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors and the targeting of adult neurological cancers.
4) Clinical management of patients with neurological cancers who undergo immunotherapy treatments.
5) The relationship between immunotherapy and CNS complications.
Please note: This Research Topic will not accept manuscripts that consist solely of bioinformatics analysis of public databases and are not accompanied by clinical or biological validation.